Fig. 3From: Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trialSchedule for assessments of irinotecan and ketogenic-diet therapy. Randomization will be performed 0 days after study initialization. Except for “a” in the figure, the other items indicate the same assessments in the two groups. The details are shown in Fig. 2. “b”: patients will be monitored for new or existing adverse events for 4 weeks after treatment discontinuation. “c”: follow-up for survival will be monitored every 3 months after treatment discontinuation until patient death or study terminationBack to article page